» Articles » PMID: 23644091

Benefit of Pulmonary Vein Isolation Guided by Loss of Pace Capture on the Ablation Line: Results from a Prospective 2-center Randomized Trial

Overview
Date 2013 May 7
PMID 23644091
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study was conducted to determine if an additional procedural endpoint of unexcitability (UE) to pacing along the ablation line reduces recurrence of atrial fibrillation (AF) or atrial tachycardia (AT) after radiofrequency catheter ablation.

Background: AF/AT recurrence is common after pulmonary vein isolation (PVI).

Methods: We included 102 patients from 2 centers (age 63 ± 10 years; 33 women; left atrium 38 ± 7 mm; left ventricular ejection fraction 61 ± 6%) with symptomatic paroxysmal AF. A 3-dimensional mapping system and circumferential mapping catheter were used in all patients for PVI. In group 1 (n = 50), the procedural endpoint was bidirectional block across the ablation line. In group 2 (n = 52), additional UE to bipolar pacing at an output of 10 mA and 2-ms pulse width was required. The primary endpoint was freedom from any AF/AT (>30 s) after discontinuation of antiarrhythmic drugs.

Results: Procedural endpoints were successfully achieved in all patients. Procedure duration was significantly longer in group 2 (185 ± 58 min vs. 139 ± 57 min; p < 0.001); however, fluoroscopy times were not different (23 ± 9 min vs. 23 ± 9 min; p = 0.49). After a follow-up of 12 months in all patients, 26 patients (52%) in group 1 versus 43 (82.7%) in group 2 were free from any AF/AT (p = 0.001) after a single procedure. No major complications occurred.

Conclusions: The use of pacing to ensure UE along the PVI line markedly improved near-term single-procedure success, compared with demonstration of bidirectional block alone. This additional endpoint significantly improved patient outcomes after PVI. (Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation; NCT01724437).

Citing Articles

Insights from optimal high-power ablation settings for anterior pulmonary vein wall isolation-A-Q-RATE POWER Trial.

Gardziejczyk P, Piotrowski R, Skrzynska-Kowalczyk M, Skowronska M, Wlazlowska-Struzik E, Niedzwiedz M J Interv Card Electrophysiol. 2025; .

PMID: 39971843 DOI: 10.1007/s10840-025-02022-x.


High Power Short Duration Atrial Fibrillation Ablation: Long-Term Predictors of Success and Recurrence - A Multivariate Analysis.

Vassallo F, Cunha C, Corsino L, Serpa E, Simoes Jr A, Hespanhol D Arq Bras Cardiol. 2024; 121(12):e20230837.

PMID: 39699452 PMC: 11634315. DOI: 10.36660/abc.20230837.


2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J J Arrhythm. 2024; 40(6):1217-1354.

PMID: 39669937 PMC: 11632303. DOI: 10.1002/joa3.13082.


Validation Strategy for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation in Long-Term Maintaining Sinus Rhythm: A Randomized Controlled Study.

Li X, Yu H, Lai S, Liao Y, Yang Y, Tian K Cardiol Res Pract. 2024; 2024:3672210.

PMID: 39445173 PMC: 11496574. DOI: 10.1155/2024/3672210.


Understanding Lesion Creation Biophysics and Improved Lesion Assessment during Radiofrequency Catheter Ablation. The Perfect Combination to Achieve Durable Lesions in Atrial Fibrillation Ablation.

Gracia E, Miranda-Arboleda A, Hoyos C, Matos C, Osorio J, Romero J Rev Cardiovasc Med. 2024; 25(2):44.

PMID: 39077337 PMC: 11263146. DOI: 10.31083/j.rcm2502044.